SIRE Veterinario, SA Selected as Distribution Partner to Launch Zomedica® Products into Costa Rica ANN ARBOR, MI / ACCESSWIRE /...
Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers...
Call Scheduled for Today at 6:30 PM ETSAN FRANCISCO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE...
GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC...
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,...
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s diseaseROCHESTER,...
GARDNER, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI) (the “Company”), a leading designer and...
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD,...
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout...
Declared development candidate MGX-001 for the treatment of hemophilia A; plans to present 12-month NHP durability study data in September...
PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenueNotable acceleration of commercial results in early Q3...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on...
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202...
Applauds first FDA approval of non-injection-based epinephrine deviceReiterates expected timing for filing of New Drug Application (NDA) for Anaphylm™ (epinephrine)...
SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome...
Media Release IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the...
Expects to report topline results in 2025 from Phase 2a influenza A human challenge study with oral CC-42344, including initial...